OncoSec Medical Incorporated Banner Image

OncoSec Medical Incorporated

  • Ticker ONCS
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
OncoSec Medical Incorporated Logo Image
  • 11-50 Employees
  • Based in San Diego, California
OncoSec Medical Incorporated (the "Company," "OncoSec," "they" or "their") is a late-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. OncoSec's lead immunotherapy investigational product candidate – TAVO™ (tavokinogene telseplasmid) – enables the intratumoral delivery of DNA-basedMore interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions. The technology, which employs electroporation, is designed to produce a controlled, localized expression of IL-12 in the tumor microenvironment, enabling the immune system to target and attack tumors throughout the body. OncoSec has built a deep and diverse clinical pipeline utilizing TAVO™ as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; with the latter potentially enabling OncoSec to address a great unmet medical need in oncology: anti-PD-1 non-responders.
OncoSec Medical Incorporated

Most Recent Annual Report

OncoSec Medical Incorporated
MOST RECENT 2021 Annual Report and Form 10K

Older/Archived Annual Reports